VANDA PHARMACEUTICALS INC. Employee-related Liabilities, Current
VANDA PHARMACEUTICALS INC. (VNDA) had Employee-related Liabilities, Current of $8.12 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:EmployeeRelatedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Employee-related Liabilities, Current $8.12M.
- 2026-03-31: Employee-related Liabilities, Current $6.68M.
- 2025-12-31: Employee-related Liabilities, Current $10.32M.
- 2025-09-30: Employee-related Liabilities, Current $8.75M.
| Period end | Employee-related Liabilities, Current |
|---|---|
| 2026-06-30 | $8.12M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $6.68M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $10.32M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $8.75M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $6.90M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $3.79M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $8.46M 10-K · filed 2026-02-12 |
| 2024-09-30 | $6.69M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $4.54M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $2.38M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $6.41M 10-K · filed 2025-02-14 |
| 2023-09-30 | $5.08M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.32M 10-Q · filed 2023-07-28 |
| 2023-03-31 | $3.14M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $6.84M 10-K · filed 2024-02-08 |
| 2022-09-30 | $5.77M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $4.71M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $3.13M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $6.51M 10-K · filed 2023-02-09 |
| 2021-09-30 | $5.43M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $4.01M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $4.11M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $10.95M 10-K · filed 2022-02-24 |
| 2020-09-30 | $8.13M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $5.54M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $3.76M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $6.60M 10-K · filed 2021-02-11 |
| 2019-09-30 | $5.49M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $4.77M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $3.73M 10-Q · filed 2019-05-03 |
| 2018-12-31 | $6.36M 10-K · filed 2020-02-26 |
| 2018-09-30 | $4.79M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $5.04M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $3.45M 10-Q · filed 2018-05-02 |
| 2017-12-31 | $5.32M 10-K · filed 2019-02-19 |
| 2017-09-30 | $4.77M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $4.03M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $2.85M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $4.29M 10-K · filed 2018-02-15 |
| 2016-09-30 | $3.07M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $2.31M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $1.47M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $468.00K 10-K · filed 2017-02-17 |
| 2015-09-30 | $2.01M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $1.89M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $1.11M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $388.00K 10-K · filed 2016-02-12 |
| 2014-09-30 | $1.59M 10-Q · filed 2014-10-27 |
| 2014-06-30 | $1.25M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $762.00K 10-Q · filed 2014-05-08 |
| 2013-12-31 | $176.00K 10-K · filed 2015-03-13 |
| 2013-09-30 | $1.30M 10-Q · filed 2013-11-08 |
| 2012-12-31 | $127.00K 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |